Who We Are

MerLion Pharma is progressing finafloxacin, a novel, highly differentiated antibacterial candidate. The compound, which has already shown potential for the treatment of urinary tract infections and the eradication of Helicobacter pylori, is being evaluated in critical care and hospital indications.  
MerLion Pharmaceuticals Pte Ltd was formed in 2002 through the privatisation of the former Centre for Natural Product Research (CNPR), a unique unit of Singapore’s Institute of Molecular and Cell Biology (IMCB). MerLion Pharma acquired all of CNPR’s assets, including its unique collection of natural product samples. The company is now focused on developing its lead antibacterial candidate, finafloxacin.